Changeflow GovPing Pharma & Drug Safety EPO Patent Application EP4709707A1: NMDA Recept...
Routine Notice Added Final

EPO Patent Application EP4709707A1: NMDA Receptor Antagonists

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4709707A1 concerning antagonists of N-methyl-D-aspartate receptors and their use. The application was filed by Fakultní Nemocnice Hradec Králové and Ustav Experimentalni Mediciny Akademie Ved Cr, v.v.i. and lists several inventors.

What changed

This document is a publication of a European patent application (EP4709707A1) related to antagonists of N-methyl-D-aspartate receptors and their therapeutic uses. The application was filed by Fakultní Nemocnice Hradec Králové and Ustav Experimentalni Mediciny Akademie Ved Cr, v.v.i., with a publication date of March 18, 2026. It includes various IPC classifications related to chemical compounds and their medical applications, specifically targeting neurological conditions.

This patent filing does not impose any new regulatory obligations on companies. It represents an intellectual property filing that may affect future research and development in the pharmaceutical sector, particularly concerning treatments for neurological disorders. Compliance officers should note this as a development in the IP landscape for relevant therapeutic areas.

Source document (simplified)

← EPO Patent Bulletin

ANTAGONISTS OF N-METHYL-D-ASPARTATE RECEPTORS AND USE THEREOF

Publication EP4709707A1 Kind: A1 Mar 18, 2026

Applicants

Fakultní Nemocnice Hradec Králové, Ustav Experimentalni Mediciny Akademie
Ved Cr, v.v.i.

Inventors

KONECNY, Jan, SVOBODOVA, Barbora, KORABECNY, Jan, SOUKUP, Ondrej, HORAK, Martin, MISIACHNA, Anna

IPC Classifications

C07C 211/42 20060101AFI20241115BHEP C07C 215/08 20060101ALI20241115BHEP C07C 15/08 20060101ALI20241115BHEP C07C 217/08 20060101ALI20241115BHEP C07D 295/033 20060101ALI20241115BHEP A61P 25/16 20060101ALI20241115BHEP A61P 25/28 20060101ALI20241115BHEP A61K 31/135 20060101ALI20241115BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

ANTAGONISTS OF N-METHYL-D-ASPARTATE RECEPTORS AND USE THEREOF

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4709707A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Intellectual Property Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Medical Research

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.